Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension

• Status: Recruiting
• Trial end date: 2021-10-31
• Target enrollment: 0
• Participant gender: All

Summary

A Randomized, Double-blind, Multicenter, Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypertension

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Handok Inc.
• Treatments: Amlodipine; Irbesartan

Criteria

Inclusion Criteria:

• Patients who are 19 years or older / 75 years or younger on screening

• Signed informed consent

• Patients with Essential Hypertension

• Other inclusion applied

Exclusion Criteria:

• Orthostatic hypertension with symptom

• Other exclusion applied